Literature DB >> 24464454

Depression, anxiety, cognitive impairment and their association with clinical and demographic variables in people with type 2 diabetes: a 4-year prospective study.

M Trento1, M Trevisan, M Raballo, P Passera, L Charrier, F Cavallo, M Porta.   

Abstract

OBJECTIVE: To investigate depression, anxiety and cognitive impairment and their associations with clinical and socio-demographic variables in type 2 diabetes.
METHODS: The Zung Self-Rating Depression-Anxiety Scale and Mini-Mental State Examination (MMSE) were administered at baseline and after 4 years to 498 consecutive patients, 249 non-insulin treated (NIT) and 249 insulin treated (IT), aged 40-80 years.
RESULTS: At baseline, IT patients were older, had longer disease duration, higher HbA1c and did more glucose monitoring (p < 0.001, all) but their depression scores were lower than among NIT (p = 0.006), with no differences for anxiety or MMSE. After 4 years, 72 patients were lost to the follow-up, of whom 18 had died. 41 NIT had switched to insulin and increased BMI (p = 0.004), blood pressure (p < 0.001), retinopathy severity (p = 0.03) and microalbuminuria (p = 0.0045), but did not change their scores for depression, anxiety or MMSE. The remaining 171 NIT improved fasting glucose (p = 0.006), total cholesterol (p < 0.0001), triglyceride (p = 0.0026) and HbA1c (p = 0.0006). Despite increased prevalence of microalbuminuria and retinopathy (p < 0.0001, both), depression (p = 0.04) and MMSE (p = 0.0007) improved. Foot ulcers (p = 0.03), retinopathy (p < 0001), microalbuminuria (p = 0.0047) and hypertension (p < 0.0001) increased in the remaining 214 IT patients, in whom depression (p = 0.0005) and anxiety (p < 0.0001) worsened while MMSE improved slightly (p = 0.0002). On multivariate analysis, depression was associated with being a woman and anxiety with diabetes duration and lower schooling, which also affected MMSE scores.
CONCLUSIONS: Depression was associated with female gender and worsening complications but not modified by diabetes duration or switching to insulin therapy. Diabetes duration and lower schooling may affect anxiety and cognitive impairment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24464454     DOI: 10.1007/s40618-013-0028-7

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  23 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Depression in diabetes: the chicken or the egg?

Authors:  Patrick J Lustman; Ray E Clouse
Journal:  Psychosom Med       Date:  2007-05       Impact factor: 4.312

3.  A prospective study of depression and mortality in patients with type 2 diabetes: the Fremantle Diabetes Study.

Authors:  D G Bruce; W A Davis; S E Starkstein; T M E Davis
Journal:  Diabetologia       Date:  2005-11-15       Impact factor: 10.122

4.  A cross-sectional survey of depression, anxiety, and cognitive function in patients with type 2 diabetes.

Authors:  M Trento; M Raballo; M Trevisan; J Sicuro; P Passera; L Cirio; L Charrier; F Cavallo; M Porta
Journal:  Acta Diabetol       Date:  2011-03-27       Impact factor: 4.280

5.  Relationship of depression and diabetes self-care, medication adherence, and preventive care.

Authors:  Elizabeth H B Lin; Wayne Katon; Michael Von Korff; Carolyn Rutter; Greg E Simon; Malia Oliver; Paul Ciechanowski; Evette J Ludman; Terry Bush; Bessie Young
Journal:  Diabetes Care       Date:  2004-09       Impact factor: 19.112

6.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

Authors:  Sarah Wild; Gojka Roglic; Anders Green; Richard Sicree; Hilary King
Journal:  Diabetes Care       Date:  2004-05       Impact factor: 19.112

7.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Prevalence and incidence of chronic complications and mortality in a cohort of type 2 diabetic patients in Spain.

Authors:  Xavier Mundet; Antonia Pou; Nuria Piquer; Maria Isabel Fernandez Sanmartin; Marc Tarruella; Rosa Gimbert; Montserrat Farrus
Journal:  Prim Care Diabetes       Date:  2008-06-27       Impact factor: 2.459

10.  Correlates of anxiety and depression among patients with type 2 diabetes mellitus.

Authors:  Yatan Pal Singh Balhara; Rajesh Sagar
Journal:  Indian J Endocrinol Metab       Date:  2011-07
View more
  9 in total

1.  Associations between comorbid anxiety, diabetes control, and overall medical burden in patients with serious mental illness and diabetes.

Authors:  Laura A Bajor; Douglas Gunzler; Douglas Einstadter; Charles Thomas; Richard McCormick; Adam T Perzynski; Stephanie W Kanuch; Kristin A Cassidy; Neal V Dawson; Martha Sajatovic
Journal:  Int J Psychiatry Med       Date:  2015-06-09       Impact factor: 1.210

2.  Associations among comorbid anxiety, psychiatric symptomatology, and diabetic control in a population with serious mental illness and diabetes: Findings from an interventional randomized controlled trial.

Authors:  Awais Aftab; Chetan Bhat; Douglas Gunzler; Kristin Cassidy; Charles Thomas; Richard McCormick; Neal V Dawson; Martha Sajatovic
Journal:  Int J Psychiatry Med       Date:  2017-12-27       Impact factor: 1.210

3.  Depression in Diabetic Patients: What Is the Link With Eating Disorders? Results of a Study in a Representative Sample of Patients With Type 1 Diabetes.

Authors:  Federica Pinna; Federico Suprani; Valeria Deiana; Lorena Lai; Mirko Manchia; Pasquale Paribello; Giulia Somaini; Enrica Diana; Eraldo Francesco Nicotra; Fernando Farci; Mariangela Ghiani; Rossella Cau; Marta Tuveri; Efisio Cossu; Elena Loy; Andrea Crapanzano; Paola Grassi; Andrea Loviselli; Fernanda Velluzzi; Bernardo Carpiniello
Journal:  Front Psychiatry       Date:  2022-06-16       Impact factor: 5.435

4.  Sertraline plus deanxit to treat patients with depression and anxiety in chronic somatic diseases: a randomized controlled trial.

Authors:  Limin Wang; Zhuoyuan Zhong; Jingyang Hu; Xiaoming Rong; Jun Liu; Songhua Xiao; Zhonglin Liu
Journal:  BMC Psychiatry       Date:  2015-04-14       Impact factor: 3.630

5.  Prevalence and determinants of depressive and anxiety symptoms in adults with type 2 diabetes in China: a cross-sectional study.

Authors:  Nianquan Sun; Peian Lou; Yan Shang; Pan Zhang; Jian Wang; Guiqiu Chang; Chunlei Shi
Journal:  BMJ Open       Date:  2016-08-16       Impact factor: 2.692

6.  Eleven-year multimorbidity burden among 637 255 people with and without type 2 diabetes: a population-based study using primary care and linked hospitalisation data.

Authors:  Salwa S Zghebi; Douglas T Steinke; Martin K Rutter; Darren M Ashcroft
Journal:  BMJ Open       Date:  2020-07-01       Impact factor: 2.692

7.  The Effect of Type 2 Diabetes Mellitus on Neuropsychological Symptoms in Chinese Early Alzheimer's Disease Population.

Authors:  Qianqian Shi; Faying Zhou; Jing Mei; Haimei Yang; Huiyun Li
Journal:  Neuropsychiatr Dis Treat       Date:  2020-03-26       Impact factor: 2.570

8.  Selected factors determining a way of coping with stress in type 2 diabetic patients.

Authors:  Anna Beata Sobol-Pacyniak; Wiesław Szymczak; Paulina Kwarta; Jerzy Loba; Tadeusz Pietras
Journal:  Biomed Res Int       Date:  2014-07-03       Impact factor: 3.411

9.  Assigning Clinical Significance and Symptom Severity Using the Zung Scales: Levels of Misclassification Arising from Confusion between Index and Raw Scores.

Authors:  Debra A Dunstan; Ned Scott
Journal:  Depress Res Treat       Date:  2018-01-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.